All News

From Kristen Dahlgren stepping away from NBC to focus on the Pink Eraser Project for cancer vaccines, to MTV’s Jared March dying of sarcoma, here’s what is happening in the oncology space this week.

Some patients with metastatic bladder cancer and FGFR3 genetic alterations may benefit from Balversa, as it “represents a critical need,” an expert said.

Patients with neuroendocrine tumors or neuroblastoma could be treated with a different approach based on a protein that may be a potential biomarker.

The 21-gene breast recurrence score may lead clinicians away from prescribing chemotherapy to Black women who could benefit from the therapy.

"Getting cancer is kind of like getting stuck out in the rain — torrential rain."

A vaccine for pancreatic and colorectal cancers is showing promise, but potential availability of the drug is likely several years away, an expert said.

Some treatment-related cardiovascular events, such as atrial fibrillation, may be more common in patients with non-small cell lung cancer, research shows.

Welireg outperformed Afinitor in time to disease progression and patient-reported quality of life in the treatment of metastatic clear cell renal cell carcinoma.

There were certain characteristics associated with a perceived loss of dignity in patients with cancer, according to recent research.

“When you have support, you have answers to some of your unknowns and that can provide stability and ease in anxiety and depression, and truly propel you into thriving,” a cervical cancer survivor and advocate tells CURE®.

The treatment combination of avutometinib and Lumakras has been granted a Fast Track designation from the FDA in some with metastatic NSCLC.

A multidose regimen of the novel human fusion protein with a treatment combination may result in prolonged survival after acute graft-versus-host-disease.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

Patients with high-risk prostate cancer who had a higher dose of radiation plus long-term androgen deprivation therapy tended to live longer than those who had a lower dose.

A cancer survivor described the agony of making a life-or-death decision.

The Food and Drug Administration will speed up their review of Enhertu for previously treated patients with certain HER2-positive solid tumors.

Real-world data demonstrated that knowing a patient’s stage and subtype of renal cell carcinoma, a type of kidney cancer, may provide cancer teams with the information needed to determine potential prognosis and recurrence risk.

Subcutaneous Opdivo led to similar outcomes to intravenous administration of the drug and may be easier to access down the road, an expert said.

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Findings from the ASCERTAIN trial support the use of oral Inqovi for adults with intermediate- and high-risk myelodysplastic syndromes (MDS) such as chronic myelomonocytic leukemia (CMML).

Fear overtook my mind as I received rounds of scans for prostate cancer when my PSA results surged.

Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.

Urinary minimal residual disease-negative status was related to preventing the return of cancer when certain patients with bladder cancer received Adstiladrin.

CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.

Postsurgical Keytruda improved disease-free survival — but not overall survival — in patients with locally advanced, muscle-invasive bladder cancer.

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.

I never told my daughters what stage my lung cancer was. Was I being genuine?